Royal Bank of Canada’s enGene Therapeutics ENGN Stock Holding History

Royal Bank of Canada’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$72K	Buy	10,545 +2,630	+33%	+$23.4K	﹤0.01%	5307
2025 Q4	$71K	Hold	7,915	–	–	﹤0.01%	5370
2025 Q3	$54K	Hold	7,915	–	–	﹤0.01%	5788
2025 Q2	$29K	Hold	7,915	–	–	﹤0.01%	6136
2025 Q1	$35K	Hold	7,915	–	–	﹤0.01%	5702
2024 Q4	$53K	Hold	7,915	–	–	﹤0.01%	5664
2024 Q3	$52K	Hold	7,915	–	–	﹤0.01%	5676
2024 Q2	$75K	Hold	7,915	–	–	﹤0.01%	5439
2024 Q1	$134K	Sell	7,915 -29,930	-79%	-$366K	﹤0.01%	5015
2023 Q4	$349K	Buy	+37,845	New	+$335K	﹤0.01%	4594

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Royal Bank of Canada's ENGN Position: Q1 2026 in Review

Royal Bank of Canada increased its enGene Therapeutics (ENGN) stake by 33% in Q1 2026, buying an estimated $23.4K and bringing the position to 10,545 shares worth $72K. The position accounts for ﹤0.01% of the portfolio, ranked #5307.

Royal Bank of Canada first reported a position in ENGN in Q4 2023 and has held it in 10 quarters since. The position peaked at $349K in Q4 2023. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

Royal Bank of Canada held 10,545 shares of enGene Therapeutics worth $72K as of Q1 2026.
Royal Bank of Canada bought 2,630 enGene Therapeutics shares in Q1 2026, an estimated $23.4K.
enGene Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5307 holding.
Royal Bank of Canada first reported a position in enGene Therapeutics in Q4 2023 and has held it in 10 quarters since.
Royal Bank of Canada's enGene Therapeutics position peaked at $349K in Q4 2023.
61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.